Bacterial and fungal biofilm infections

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 415-428

  Lynch, A Simon ^a   Robertson, Gregory T ^a  

^a Cumbre Pharmaceuticals Inc   (United States)

Author keywords

Antibiotic; Antibiotic resistance; Antibiotic tolerance; Indwelling medical device; Persistent infection; Staphylococcal infections

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA LACTAM ANTIBIOTIC; CASPOFUNGIN; CBR 2092; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ECHINOCANDIN; FURANONE DERIVATIVE; FUSIDIC ACID; LINEZOLID; LYSOSTAPHIN; MICAFUNGIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BIOFILM; DEVICE; DEVICE INFECTION; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INDWELLING CATHETER; LONG TERM CARE; MORBIDITY; MORTALITY; MYCOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS; TREATMENT INDICATION; TREATMENT OUTCOME;

BACTERIAL INFECTIONS; BIOFILMS; HEALTH CARE COSTS; HUMANS; MYCOSES; PROSTHESIS-RELATED INFECTIONS;

EID: 39649107354     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.110106.132000     Document Type: Review

References (84)

1. Purevdorj-Gage LB, Stoodley P. 2004. Biofilm structure, behavior, and hydrodynamics. See Ref. 1a, pp. 160-73
2. Ghannoum M, O'Toole GA, eds. 2004. Microbial Biofilms. Washington, DC: ASM Press
3. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167-93
4. Cvitkovitch DG. 2004. Genetic exchange in biofilms. See Ref. 1a, pp. 192-205
5. Weigel LM, Donlan RM, Shin DH, et al. 2007. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob. Agents Chemother. 51:231-38
6. Parsek MR, Singh PK. 2003. Bacterial biofilms: an emerging link to disease pathogenesis. Annu. Rev. Microbiol. 57:677-701
7. Thomas JG, Litton I, Rinde H. 2006. Economic impact of biofilms on treatment costs. See Ref. 6a, pp. 21-38
8. Pace JL, Rupp ME, Finch RG. 2006. Biofilms, Infection, and Antimicrobial Therapy. Boca Raton, FL: CRC Press
9. Darouiche RO. 2001. Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 33:1567-72
10. Fux CA, Stoodley P, Hall-Stoodley L, et al. 2003. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev. Anti Infect. Ther. 1:667-83
11. Goeau-Brissonniere OA, Coggia M. 2000. Arterial prosthetic infections. See Ref. 9a, pp. 127-44
12. Waldvogel FA, Bisno AL, eds. 2000. Infections Associated with Indwelling Medical Devices. Washington, DC: ASM Press
13. Steckelberg JM, Osmon DR. 2000. Prosthetic joint infections. See Ref. 9a, pp. 173-209
14. Trampuz A, Widmer AF. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349-56
15. Cranton SE, Gotz F. 2004. Biofilm development in Staphylococcus. See Ref. 1a, pp. 64-84
16. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-67
17. Ramage G, Saville SP, Thomas DP, et al. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-38
18. Hawser S, Islam K. 2006. Candida. See Ref. 6a, pp. 171-84
19. Chandra J, Ghannoum A. 2004. Fungal biofilms. See Ref. 1a, pp. 30-42
20. Fridkin SK, Kaufman D, Edwards JR, et al. 2004. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 117:1680-87
21. Anderson JM, Marchant RE. 2000. Biomaterials: factors favoring colonization and infection. See Ref. 9a, pp. 89-109
22. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-22
23. Hansen SK, Rainey PB, Haagensen JA, et al. 2007. Evolution of species interactions in a biofilm community. Nature 445:533-36
24. Wargo MJ, Hogan DA. 2006. Fungal-bacterial interactions: a mixed bag of mingling microbes. Curr. Opin. Microbiol. 9:359-64
25. Anderson GG, Dodson KW, Hooton TM, et al. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105-7
26. Hall-Stoodley L, Hu FZ, Gieseke A, et al. 2006. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 296:202-11
27. Murray TS, Egan M, Kazmierczak BI. 2007. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19:83-88
28. Darouiche RO. 2004. Treatment of infections associated with surgical implants. N. Engl. J. Med. 350:1422-29
29. Engemann JJ, Friedman JY, Reed SD, et al. 2005. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect. Control Hosp. Epidemiol. 26:534-39
30. Reed SD, Friedman JY, Engemann JJ, et al. 2005. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 26:175-83
31. Meier-Davis S. 2006. Host responses to biofilms. See Ref. 6a, pp. 305-27
32. Gillis RJ, White KG, Choi KH, et al. 2005. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 49:3858-67
33. Hancock V, Klemm P. 2007. Global gene expression profiling of asymptomatic bacteriuria Escherichia coli during biofilm growth in human urine. Infect. Immun. 75:966-76
34. Andes D, Nett J, Oschel P, et al. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 72:6023-31
35. Mukherjee PK, Chandra J, Kuhn DM, et al. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-40
36. Cerca N, Martins S, Cerca F, et al. 2005. Comparative assessment of antibiotic susceptibility of coagulase-negative staphylococci in biofilm versus planktonic culture as assessed by bacterial enumeration or rapid XTT colorimetry. J. Antimicrob. Chemother. 56:331-36
37. Proctor RA, von Eiff C, Kahl BC, et al. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4:295-305
38. von Gotz F, Haussler S, Jordan D, et al. 2004. Expression analysis of a highly adherent and cytotoxic small colony variant of Pseudomonas aeruginosa isolated from a lung of a patient with cystic fibrosis. J. Bacteriol. 186:3837-47
39. Roggenkamp A, Sing A, Hornef M, et al. 1998. Chronic prosthetic hip infection caused by a small-colony variant of Escherichia coli. J. Clin. Microbiol. 36:2530-34
40. Chatterjee I, Herrmann M, Proctor RA, et al. 2007. Enhanced post-stationary-phase survival of a clinical thymidine-dependent small-colony variant of Staphylococcus aureus results from lack of a functional tricarboxylic acid cycle. J. Bacteriol. 189:2936-40
41. Lewis K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48-56
42. Falagas ME, Fragoulis K, Bliziotis IA, et al. 2007. Rifampicin- impregnated central venous catheters: a meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 59:359-69
43. Manierski C, Besarab A. 2006. Antimicrobial locks: putting the lock on catheter infections. Adv. Chronic Kidney Dis. 13:245-58
44. Zimmerli W, Trampuz A, Ochsner PE. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-54
45. Trampuz A, Zimmerli W. 2006. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 66:1089-105
46. Stein A, Drancourt M, Raoult D. 2000. Ambulatory management of infected orthopedic implants. See Ref. 9a, pp. 211-30
47. Antonios V, Berbari E, Osmon D. 2006. Treatment protocols for infections of orthopedic devices. See Ref. 6a, pp. 449-78
48. Lewis RE, Raad II. 2006. Treatment protocols for infections of vascular catheters. See Ref. 6a, pp. 409-25
49. Karchmer AW. 2000. Infections of prosthetic heart valves. See Ref. 9a, pp. 145-72
50. Stryjewski ME, Corey GR. 2006. Treatment protocols for bacterial endocarditis and infection of electrophysiologic cardiac devices. See Ref. 6a, pp. 427-48
51. Yogev R, Bisno AL. 2000. Infections of central nervous system shunts. See Ref. 9a, pp. 231-46
52. Eggimann P, Waldvogel F. 2000. Pacemaker and defibrillator infections. See Ref. 9a, pp. 247-64
53. Dever LL, Johanson WGJ. 2000. Infections associated with endotracheal intubation and tracheostomy. See Ref. 9a, pp. 307-24
54. Oliver MJ, Schwab SJ. 2000. Infections related to hemodialysis and peritoneal dialysis. See Ref. 9a, pp. 345-72
55. Hessen MT, Zuckerman JM, Kaye D. 2000. Infections associated with foreign bodies in the urinary tract. See Ref. 9a, pp. 325-44
56. Widmer AF, Gaechter A, Ochsner PE, et al. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-53
57. Zimmerli W, Widmer AF, Blatter M, et al. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 279:1537-41
58. Schrenzel J, Harbarth S, Schockmel G, et al. 2004. A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin. Infect. Dis. 39:1285-92
59. Drancourt M, Stein A, Argenson JN, et al. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob. Agents Chemother. 37:1214-18
60. Isiklar ZU, Demirors H, Akpinar S, et al. 1999. Two-stage treatment of chronic staphylococcal orthopaedic implant-related infections using vancomycin impregnated PMMA spacer and rifampin containing antibiotic protocol. Bull. Hosp. Joint Dis. 58:79-85
61. Drancourt M, Stein A, Argenson JN, et al. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39:235-40
62. Soustre J, Rodier MH, Imbert-Bouyer S, et al. 2004. Caspofungin modulates in vitro adherence of Candida albicans to plastic coated with extracellular matrix proteins. J. Antimicrob. Chemother. 53:522-25
63. Shuford JA, Rouse MS, Piper KE, et al. 2006. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. 194:710-13
64. Ehrlich G, Hu FZ, Lin Q, et al. 2004. Intelligent implants to battle biofilms. Am. Soc. Microbiol. News 70:127-33
65. Hazan Z, Zumeris J, Jacob H, et al. 2006. Effective prevention of microbial biofilm formation on medical devices by low-energy surface acoustic waves. Antimicrob. Agents Chemother. 50:4144-52
66. van der Borden AJ, Maathuis PG, Engels E, et al. 2007. Prevention of pin tract infection in external stainless steel fixator frames using electric current in a goat model. Biomaterials 28:2122-26
67. Ensing GT, Neut D, van Horn JR, et al. 2006. The combination of ultrasound with antibiotics released from bone cement decreases the viability of planktonic and biofilm bacteria: an in vitro study with clinical strains. J. Antimicrob. Chemother. 58:1287-90
68. Laplante KL, Mermel LA. 2007. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol. Dial. Transplant. 22:2239-46
69. Raad I, Darouiche R, Vazquez J, et al. 2005. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infections caused by gram-positive pathogens. Clin. Infect. Dis. 40:374-80
70. Drew RH, Perfect JR, Srinath L, et al. 2000. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J. Antimicrob. Chemother. 46:775-84
71. Razonable RR, Osmon DR, Steckelberg JM. 2004. Linezolid therapy for orthopedic infections. Mayo Clin. Proc. 79:1137-44
72. Saginur R, Stdenis M, Ferris W, et al. 2006. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob. Agents Chemother. 50:55-61
73. Combrink KD, Lynch AS. 2007. New rifamycins for the treatment of bacterial infections. Expert Opin. Ther. Patents 17:475-85
74. Pinkner JS, Remaut H, Buelens F, et al. 2006. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Sci. USA 103:17897-902
75. Anguita-Alonso P, Giacometti A, Cirioni O, et al. 2007. RNAIII-inhibiting peptide-loaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm formation. Antimicrob. Agents Chemother. 51:2594-96
76. Muh U, Hare BJ, Duerkop BA, et al. 2006. A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc. Natl. Acad. Sci. USA 103:16948-52
77. Hume EB, Baveja J, Muir B, et al. 2004. The control of Staphylococcus epidermidis biofilm formation and in vivo infection rates by covalently bound furanones. Biomaterials 25:5023-30
78. Kaneko Y, Thoendel M, Olakanmi O, et al. 2007. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 117:877-88
79. Raad I, Hanna H, Jiang Y, et al. 2007. Comparative activity of daptomycin, linezolid and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob. Agents Chemother. 51:1656-60
80. Fowler VG Jr, Boucher HW, Corey GR, et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-65
81. Blaser J, Vergeres P, Widmer AF, et al. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-39
82. Giacometti A, Cirioni O, Ghiselli R, et al. 2005. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus. Antimicrob. Agents Chemother. 49:4042-45
83. Gander S, Kinnaird A, Finch R. 2005. Telavancin: in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 56:337-43
84. Yin LY, Lazzarini L, Li F, et al. 2005. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J. Antimicrob. Chemother. 55:995-1002